FIELD: medicine, endocrinology.
SUBSTANCE: invention relates to treatment of diabetes mellitus in mammals. Invention proposes applying inhibitors of enzyme dipeptidyl peptidase IV as an active component in manufacturing a medicinal agent, and in a method for treatment of diabetes mellitus. Invention provides enhancing the functional activity of insulin-producing cells in animal and differentiation of epithelial cells of the pancreas.
EFFECT: improved method for insulin producing and diabetes treatment.
20 cl, 5 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT CONTAINING COMBINED USE OF COMBINATION OF DPP-IV INHIBITOR AND OTHER THERAPEUTIC AGENT FOR TREATING DIABETES | 2009 |
|
RU2523552C2 |
| NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND USES THEREOF AS HYPOTENSIVE AGENT | 2002 |
|
RU2305553C2 |
| APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
| TREATMENT OF DIABETES TYPE 2 WITH INHIBITORS OF DIPEPTIDYLPAPTIDASE IV | 2002 |
|
RU2328283C2 |
| USE OF EFFECTORS DECREASING ACTIVITY OF DIPEPTIDYL-PEPTIDASE (DP IV) AND ENZYME DP IV RESPECTIVELY WITH SIMILAR ACTIVITY FOR DECREASE OF BLOOD GLUCOSE LEVEL | 1997 |
|
RU2189233C2 |
| PHARMACEUTICAL COMBINATION CONTAINING SGLT2 INHIBITOR | 2008 |
|
RU2489151C2 |
| METHOD FOR PREVENTING GLP-1 SIDE EFFECTS | 2008 |
|
RU2474415C2 |
| METHYL(R)-7-[3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYRYL]-3-TRIFLUOROMETHYL-5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE-1-CARBOXYLATE SALTS | 2010 |
|
RU2528233C2 |
| METHODS FOR SGLT2 INHIBITOR OBTAINING AND APPLICATION | 2013 |
|
RU2643764C2 |
| DRUG FOR PREVENTION AND TREATMENT OF DIABETES | 2013 |
|
RU2597848C2 |
